WT1 Peptide Cancer Vaccine for Glioma
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Immunotherapy is considered the "fourth treatment" alongside surgery, radiotherapy, and chemotherapy. Research at Osaka University Graduate School of Medicine found that WT1 is detected in a high proportion of various tumors. Consequently, in 2001, they began translational research on the WT1 peptide cancer vaccine. To date, over 800 patients with various solid tumors (besides leukemia) have received the vaccine. No serious side effects have been reported, and significant effectiveness has been shown in difficult-to-treat solid tumors such as leukemia, pancreatic cancer, and brain tumors.
-
In 2010, it was discovered that for patients with malignant glioma treated with radiotherapy and Temozolomide, the first-phase clinical trial of the WT1 peptide cancer vaccine showed a 2-year survival rate of 100% and a 5-year survival rate of 57%. Compared to the standard treatment's 2-year survival rate of 25% and 5-year survival rate of less than 10%, the combination with the WT1 cancer vaccine has garnered significant attention.
-
Similarly, for patients with recurrent malignant glioma, a clinical trial was conducted using a "cocktail" cancer vaccine mixing WT1 killer peptide and WT1 helper peptide. This trial also involved inducing WT1-specific CD8-positive T cells and WT1-specific CD4-positive T cells. Long-term continuous observation for over a year revealed highly significant immune responses.
The research laboratory also published some fundamental research findings in 2017 regarding the mechanism of action of the WT1 peptide cancer vaccine. Interested readers are welcome to refer to those materials.
Note: According to Wikipedia, translational medicine (also known as translational research) is a new paradigm that aims to bridge the gap between basic medical research and clinical treatment. The concept was first introduced by Elias A. Zerhouni, Director of the National Institutes of Health (NIH), in an article titled "US Biomedical Research-Basic, Translational, and Clinical Sciences" published in JAMA.
In the past, basic medicine, drug development, and clinical treatment were separate fields. However, advancements in biotechnology have allowed for large-scale analysis of research targets. Coupled with statistical analysis in bioinformatics, these three previously separate fields have become rapidly interconnected. This is the essence of translational medicine—applying the findings of molecular pathogenesis research directly to clinical treatment.
[Precautions] The clinical trial data and medical information translated by "Medical Supporter" are for reference only and do not constitute a recommendation for the use of any specific drugs or participation in clinical trials. Please consult with medical professionals for appropriate medical guidance. The original source text at the bottom of the article should be considered the definitive version.
Source: Osaka University Graduate School of Medicine HP http://www.med.osaka-u.ac.jp/introduction/research/endowed/immunotherapy
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5